These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's Why it is Prudent for Investors to Hold Humana Stock for Now
HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.
Should Value Investors Buy Humana (HUM) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...
Texas A&M University-Mays Business School and Humana Announce Winners of Eighth Annual Healthcare Analytics Case Competition
BRYAN-COLLEGE STATION, Texas--(BUSINESS WIRE)--Texas A&M University-Mays Business School and Humana announce winners of 8th annual Healthcare Analytics Case Competition.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact ...
Humana - Q3 Earnings Review: The Medicare Advantage Madness May Finally Be Over
Humana's stock has fallen over 30% due to rising healthcare utilization and CMS pushing back on insurer profits, impacting MA-focused companies. Despite headwinds, Humana's Q3 earnings showed resil...
Humana Q3 Earnings Beat on Growing Premiums & Cost Management
Better-than-expected Medicare Advantage membership aids HUM's third-quarter results.
Humana updates profit guidance as Q3 results top estimates
Humana (NYSE:HUM), a for-profit American health insurance firm, reported a beat on the top and bottom lines for the third quarter and strengthened its full year profit guidance, sending its shares ...
Humana (HUM) Q3 Earnings and Revenues Beat Estimates
Humana (HUM) came out with quarterly earnings of $4.16 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $7.78 per share a year ago.
Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?
HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.
HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Humana Inc. and Encourages Investors to Contact the Firm
NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (“Humana” or “the Com...
HUMANA ALERT: Bragar Eagel & Squire, P.C. is Investigating Humana Inc. on Behalf of Humana Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humana Inc. (“Humana” or the ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to cont...
Watch These Humana Price Levels as Stock Jumps on Report of Merger Talks
Humana (HUM) shares surged in premarket trading Monday after Bloomberg reported late Friday that Cigna (CI) has resumed its efforts to merge with the struggling health insurer.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humana Inc. (HUM) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE:HUM...
Related Companies